Because CD38 expression is higher in the early stages of the disease, and mAbs greatly rely on the immune system to exploit their anti-MM activity, it seems reasonable to expect that moving daratumumab to the first-line setting, when the immune-system of a treatment-naïve patient is less compromised, could increase its efficacy. This evidence concerns the gene CD38 and Miyoshi myopathy.